Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer

Autor: Peters, M., van der Voort van Zyp, J.R.N., Moerland, M.A., Hoekstra, C.J., van de Pol, S., Westendorp, H., Maenhout, M., Kattevilder, R., Verkooijen, H.M., van Rossum, Peter S.N., Ahmed, H.U., Shah, T.T., Emberton, M., van Vulpen, M.

Publikováno v: In Brachytherapy May-June 2016 15(3):296-305

OC-0039 Predicting biochemical failure after MR-guided focal HDR brachytherapy for recurrent prostate cancer

Autor: Willigenburg, T., van Son, M., van de Pol, S., Eppinga, W., Lagendijk, J., Moerland, M., de Boer, H., van der Voort van Zyp, J., Peters, M.

Publikováno v: In Radiotherapy and Oncology May 2021 158 Supplement 1:S25-S27

PO-1940 Online adaptive CBCT-guided VMAT radiotherapy using an Elekta Synergy CBCT-linac

Autor: Groot Koerkamp, M., Bol, G., Kroon, P., Scheeren, A., Zoetelief, A., Krikke, L., Harderwijk, T., Plat, A., van der Vegt, S., Hes, J., van Gasteren, I., Schimmel-de Kogel, G., Renders, E., van Kaam, J., Onnink-Vijfvinke, R., Winkel, D., van Rijssel, M., Wopereis, A., Noteboom, J., van de Pol, S., Eppinga, W., van der Voort van Zyp, J., van Es, C., Bossenga, J., Raaymakers, B.

Publikováno v: In Radiotherapy and Oncology May 2023 182 Supplement 1:S1695-S1696

OC-0295 MRI-guided robotic needle insertion for prostate brachytherapy: proof of principle patient study

Autor: Moerland, M., van Lier, A., van Schelven, L., Rasing, M., Peters, M., Boskovic, E., Schokker, R., van Vliet-van den Ende, K., Kelder, D., Verkerk, J., van de Pol, S., Lagendijk, J., van der Voort van Zyp, J.

Publikováno v: In Radiotherapy and Oncology May 2023 182 Supplement 1:S230-S231

Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy.

Autor: Rasing M; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., van Son M; Department of Urology, Amsterdam University Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Moerland M; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., de Keizer B; Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Wessels F; Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Jonges T; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., van de Pol S; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Eppinga W; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Noteboom J; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Lagendijk J; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., van der Voort van Zijp J; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Peters M; Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2022 Feb 03; Vol. 14 (3). Date of Electronic Publication: 2022 Feb 03.